Literature DB >> 27020692

Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies.

L Li1, D-W Liu2, H-Y Yan3, Z-Y Wang4, S-H Zhao1, B Wang1.   

Abstract

BACKGROUND: The association between obesity and nonalcoholic fatty liver disease (NAFLD) has not been fully quantified, and the magnitude of NAFLD risk associated with obesity is still unclear. A meta-analysis of cohort studies was performed to elucidate the NAFLD risk associated with obesity.
METHODS: Pubmed, Web of Science and Embase were searched for cohort studies assessing NAFLD risk associated with obesity or increased body mass index (BMI). Relative risks (RRs) with 95% confidence intervals (95%CIs) were pooled using random-effects model of meta-analysis.
RESULTS: Twenty-one cohort studies including 13 prospective studies and 8 retrospective studies were finally included. There were a total of 381,655 participants in the meta-analysis. Compared with normal weight, obesity independently led to a 3.5-fold increased risk of developing NAFLD (RR = 3.53, 95%CI 2.48 to 5.03, P < 0.001). Meta-analysis also suggested an obvious dose-dependent relationship between BMI and NAFLD risk (per 1-unit increment in BMI: RR = 1.20, 95%CI 1.14 to 1.26, P < 0.001). Subgroup analyses further identified the robustness of the association above. No obvious risk of publication bias was observed.
CONCLUSION: Obese individuals have a 3.5-fold increased risk of developing NAFLD, and there is an obvious dose-dependent relationship between BMI and NAFLD risk.
© 2016 World Obesity. © 2016 World Obesity.

Entities:  

Keywords:  nonalcoholic fatty liver disease; obesity; risk factor

Mesh:

Year:  2016        PMID: 27020692     DOI: 10.1111/obr.12407

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  86 in total

1.  Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease.

Authors:  Chunjiong Wang; Wenli Liu; Liu Yao; Xuejiao Zhang; Xu Zhang; Chenji Ye; Hongfeng Jiang; Jinlong He; Yi Zhu; Ding Ai
Journal:  Br J Pharmacol       Date:  2017-06-09       Impact factor: 8.739

2.  Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.

Authors:  Eric K Kwong; Xiaojiaoyang Li; Phillip B Hylemon; Huiping Zhou
Journal:  Curr Pharmacol Rep       Date:  2017-06-20

3.  Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer.

Authors:  Aida Moeini; Hiroko Machida; Tsuyoshi Takiuchi; Erin A Blake; Marianne S Hom; Toshio Miki; Osamu Matsuo; Koji Matsuo
Journal:  Clin Appl Thromb Hemost       Date:  2016-08-31       Impact factor: 2.389

Review 4.  Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

Authors:  Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz
Journal:  J Nephrol       Date:  2020-05-21       Impact factor: 3.902

5.  What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?

Authors:  Mariana V Machado; Sara Policarpo; J Coutinho; Sofia Carvalhana; Jorge Leitão; Armando Carvalho; Ana P Silva; Francisco Velasco; Isabel Medeiros; Ana Catarina Alves; Mafalda Bourbon; Helena Cortez-Pinto
Journal:  Obes Surg       Date:  2020-02       Impact factor: 4.129

6.  Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture.

Authors:  Uday C Ghoshal; Chalamalasetty Sreenivasa Baba; Ujjala Ghoshal; George Alexander; Asha Misra; Vivek A Saraswat; Gourdas Choudhuri
Journal:  Indian J Gastroenterol       Date:  2017-10-16

7.  Childhood Adiposity and Nonalcoholic Fatty Liver Disease in Adulthood.

Authors:  Yinkun Yan; Dongqing Hou; Xiaoyuan Zhao; Junting Liu; Hong Cheng; Youfa Wang; Jie Mi
Journal:  Pediatrics       Date:  2017-04       Impact factor: 7.124

8.  Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus.

Authors:  Mojtaba Malek; Mohammad E Khamseh; Haleh Chehrehgosha; Sohrab Nobarani; Fariba Alaei-Shahmiri
Journal:  Endocrine       Date:  2021-08-05       Impact factor: 3.633

9.  Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.

Authors:  Aline de Conti; Volodymyr Tryndyak; Rose A Willett; Barbara Borowa-Mazgaj; Anna Watson; Ralph Patton; Sangeeta Khare; Levan Muskhelishvili; Greg R Olson; Mark I Avigan; Carl E Cerniglia; Sharon A Ross; Arun J Sanyal; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  FASEB J       Date:  2020-04-18       Impact factor: 5.191

10.  Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Hu Wang; Li Wang; Yujia Cheng; Zhiqing Xia; Yifeng Liao; Jiang Cao
Journal:  Biomed Rep       Date:  2018-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.